The FDA has approved Geron Corporation’s drug, imetelstat, for the treatment of anemia in adults with low- to intermediate-risk myelodysplastic syndromes. This marks the company’s first commercialized product and provides competition against Bristol Myers Squibb’s blockbuster drug. The approval is based on the drug’s ability to enable bone marrow recovery and normal red blood cell production by blocking telomerase, an enzyme involved in cancer cell proliferation. Clinical trials showed positive results, with a significant percentage of patients becoming transfusion-independent. Rytelo is administered via intravenous infusion every two weeks and has a wholesale price ranging from $2,741 to $9,884 per vial.
Source link
Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer
